1 00:00:06,480 --> 00:00:09,760 Welcome back to Translating Proteomics. Today I'm very pleased 2 00:00:09,760 --> 00:00:12,720 to be chatting with Professor Priyanka Joshi from Georgetown University. 3 00:00:12,960 --> 00:00:16,400 Priyanka completed her PhD in chemistry with Professor Michaela 4 00:00:16,400 --> 00:00:20,680 Vendriscalo at Cambridge and was awarded a junior Research fellowship 5 00:00:20,680 --> 00:00:24,400 to build her independent research program in Professor Sir 6 00:00:24,400 --> 00:00:28,240 Chris Dobson's lab at Cambridge. She then later completed 7 00:00:28,240 --> 00:00:33,540 research with Paolo Piccotti at ETH Zurich and an additional bit 8 00:00:33,540 --> 00:00:37,100 of training with Dr. Dennis Titov at UC Berkeley. And her lab 9 00:00:37,100 --> 00:00:42,140 at Georgetown investigates biophysical mechanisms by which metabolites 10 00:00:42,140 --> 00:00:46,660 contribute to protein homeostasis. A lot of her work focuses 11 00:00:46,660 --> 00:00:49,500 on what are known as intrinsically disordered proteins. 12 00:00:50,060 --> 00:00:53,660 These proteins have incredibly dynamic structures that enable them 13 00:00:53,660 --> 00:00:58,430 to take on a variety of roles in cells. And this dynamism makes. 14 00:00:58,580 --> 00:01:04,100 Makes them have an incredibly wide range of capabilities, but also 15 00:01:04,180 --> 00:01:08,100 makes them prone to an incredibly wide range of bad behavior, 16 00:01:08,260 --> 00:01:11,540 particularly in diseases like Alzheimer's, where they can aggregate. 17 00:01:13,380 --> 00:01:16,540 These proteins are also often very hard to monitor or to develop 18 00:01:16,540 --> 00:01:20,220 therapeutics against because we just don't have great tools for 19 00:01:20,220 --> 00:01:23,100 examining their dynamic structures. But Priyanka has been 20 00:01:23,100 --> 00:01:27,370 developing new amazing technologies and approaches to study 21 00:01:27,370 --> 00:01:31,050 them ever since her time as a graduate student. So we're incredibly 22 00:01:31,050 --> 00:01:34,450 fortunate to have Priyanka on today to discuss her research and 23 00:01:34,450 --> 00:01:39,130 intrinsically disordered proteins. And so, Priyanka, welcome. 24 00:01:39,130 --> 00:01:40,570 Thanks so much for being on the show. 25 00:01:41,210 --> 00:01:44,410 Thank you so much, Parag. I'm really excited and it's so much fun 26 00:01:45,370 --> 00:01:49,050 to talk about IDPs, because I've been talking about them for 27 00:01:49,290 --> 00:01:53,970 more than a decade now. But also the interest. Yeah, thank you 28 00:01:53,970 --> 00:01:54,970 so much for having me. 29 00:01:55,210 --> 00:02:00,410 Oh, yeah, absolutely. Well, so let's, let's start there and maybe 30 00:02:00,730 --> 00:02:03,170 go back in time. So you mentioned you've been studying them 31 00:02:03,170 --> 00:02:07,850 for a long time. What was your first experience with IDPs and why 32 00:02:07,850 --> 00:02:10,170 did you choose to study IDPS in the first place? 33 00:02:11,290 --> 00:02:15,290 Okay, so I did not choose to study IDPs. I feel like the other 34 00:02:15,290 --> 00:02:17,730 way around. Like, you know, if I can joke around and say, like, 35 00:02:17,730 --> 00:02:21,690 they chose me. So I did my undergrad in bioinformatics in the 36 00:02:21,690 --> 00:02:26,670 University of Pune in India, and I was introduced to this subject 37 00:02:26,670 --> 00:02:30,630 called bioinformatics, which essentially had to learn about these 38 00:02:30,710 --> 00:02:35,510 matrices, the single letter amino acid code. And I must say that 39 00:02:35,910 --> 00:02:40,910 it's kind of a full circle because the matrices that were constructed 40 00:02:40,910 --> 00:02:44,350 by Margaret Dayhoff, she was at Georgetown. So now I'm here and 41 00:02:44,350 --> 00:02:48,190 I'm studying using that single letter amino acid code in AI approaches 42 00:02:48,190 --> 00:02:51,390 to Understand how these proteins fold. So that was my first 43 00:02:51,390 --> 00:02:56,310 introduction to proteins, I would say. But then for my PhD at 44 00:02:56,550 --> 00:03:03,090 Cambridge, I was a research fellow as part of this consortium 45 00:03:03,250 --> 00:03:07,490 which was funded by the Marie Curie actions by the European Union, 46 00:03:07,650 --> 00:03:11,130 called IDP by nmr. So intrinsically disordered proteins 47 00:03:11,130 --> 00:03:15,410 by nuclear magnetic resonance. And this was a large consortium comprising 48 00:03:15,410 --> 00:03:20,410 of all the stalwarts, all the experts of idp. So from day one I 49 00:03:20,410 --> 00:03:24,690 was kind of born into these people who were talking IDPs and 50 00:03:25,090 --> 00:03:28,570 were experts. And the problem that I was given was that you have 51 00:03:28,570 --> 00:03:32,310 to design drugs for idp. So I knew I wanted to design drugs. But 52 00:03:32,310 --> 00:03:35,190 then in my textbooks, you know, back from India, like I had 53 00:03:35,190 --> 00:03:40,630 read that proteins take this globular structure, like enzymes 54 00:03:40,630 --> 00:03:44,550 and they, you know, you need that. It's like sequence to structure 55 00:03:44,550 --> 00:03:48,510 to function. But then in this consortium that paradigm was broken, 56 00:03:48,510 --> 00:03:51,470 which was, I mean the thought was like, no, in the textbooks you 57 00:03:51,470 --> 00:03:55,430 have the sequence. They can have many different structures depending 58 00:03:55,430 --> 00:04:00,160 on their binding partners and they are like promiscuous in nature 59 00:04:00,560 --> 00:04:03,640 and depending on what they interact with, that is what leads 60 00:04:03,640 --> 00:04:08,040 to function. So this was like amazingly captivating and I was like, 61 00:04:08,040 --> 00:04:10,800 this is, it was a very exciting and challenging problem. 62 00:04:11,040 --> 00:04:15,080 And also I love physics. So it was like I was, I could use, you 63 00:04:15,080 --> 00:04:18,440 know, NMR and computational methods to study. So that was like 64 00:04:18,440 --> 00:04:21,200 my first, first introduction to it. 65 00:04:21,360 --> 00:04:24,280 Yeah, I mean so you were, you were, from day one, you were recognizing 66 00:04:24,280 --> 00:04:27,720 that the paradigm of how biology works, this sequence structure 67 00:04:27,720 --> 00:04:35,100 funct is sort of a gross oversimplification. And so maybe 68 00:04:35,100 --> 00:04:38,300 just for folks who aren't familiar, tell us just a little bit, 69 00:04:38,380 --> 00:04:41,180 what are intrinsically disordered proteins or intrinsically 70 00:04:41,180 --> 00:04:45,420 disordered regions? What do they do in the cell? 71 00:04:46,540 --> 00:04:51,020 Yeah, so intrinsically disordered regions are basically, 72 00:04:51,100 --> 00:04:54,740 they are disordered across their backbone. So they would not 73 00:04:54,740 --> 00:04:59,610 occur. Like they do not have a fixed three dimensional structure. 74 00:04:59,930 --> 00:05:03,610 So at any given time they would occupy many, many like they 75 00:05:03,610 --> 00:05:05,930 would be transient. So you could have like random coil, you'll 76 00:05:05,930 --> 00:05:09,530 have alpha, the alpha helix. And they will, they will keep changing. 77 00:05:09,530 --> 00:05:13,210 So they will populate an ensemble of structures and this, 78 00:05:13,370 --> 00:05:17,610 this transient nature happens like super, super fast that it's 79 00:05:17,610 --> 00:05:20,610 incredibly hard to capture what is the structure that is, that 80 00:05:20,610 --> 00:05:24,580 is going to be taken. And what's interesting about these proteins 81 00:05:24,580 --> 00:05:30,900 is that they assume their function by their interacting by 82 00:05:30,900 --> 00:05:33,380 their partner. So they might have a different structure before, 83 00:05:33,700 --> 00:05:38,100 but when they come in contact with the binding partner and that's 84 00:05:38,100 --> 00:05:42,580 when they are assuming the function and Also what's been seen 85 00:05:42,580 --> 00:05:47,100 is that they have residues that are quite peculiar. There could 86 00:05:47,100 --> 00:05:51,300 be some residues that are more disordered oriented. And that's how 87 00:05:51,300 --> 00:05:54,100 a lot of databases have been constructed, like, you know, for 88 00:05:54,100 --> 00:05:57,420 sequence based properties that can predict disorder in a protein. 89 00:05:57,580 --> 00:05:59,820 And something I tell my students all the time is like, if 90 00:05:59,820 --> 00:06:02,140 you've been given a protein sequence because everyone wants to 91 00:06:02,140 --> 00:06:04,940 use alpha fold right now, please give that sequence, like put 92 00:06:04,940 --> 00:06:07,900 that sequence in alpha fold. And the kind of proteins we study, 93 00:06:07,900 --> 00:06:12,100 they come back with like 5% confidence or something. And, and 94 00:06:12,100 --> 00:06:16,310 that's when the story starts, which is like, you know, a lot of, 95 00:06:16,870 --> 00:06:21,230 I mean, the protein data bank has structured proteins. So all the 96 00:06:21,230 --> 00:06:25,950 missing electron densities were disordered regions. And you 97 00:06:25,950 --> 00:06:26,230 know,. 98 00:06:26,470 --> 00:06:29,590 So I think when people think about proteins, they, and they think 99 00:06:29,590 --> 00:06:31,790 about protein structures, they're like, okay, well there are 100 00:06:31,790 --> 00:06:35,230 loop regions and like the loop regions are floppy. But that's not 101 00:06:35,230 --> 00:06:37,550 what you're talking about. You're not talking about an arbitrary 102 00:06:37,550 --> 00:06:40,630 floppy loop region. You're talking about an entire region of 103 00:06:40,630 --> 00:06:44,350 the protein that might have a hundred different shapes that it 104 00:06:44,350 --> 00:06:48,710 assumes, some of which look and are, you know, briefly structured 105 00:06:48,790 --> 00:06:52,270 or transition through structured regions. But it's, it's 106 00:06:52,270 --> 00:06:55,150 really that diversity. It's not just like, oh, I don't assume 107 00:06:55,150 --> 00:06:59,150 any shape, it's that I have specific families of shapes that 108 00:06:59,150 --> 00:07:02,150 I might adopt in a context dependent manner. 109 00:07:02,550 --> 00:07:08,150 Exactly. That is right. And you can think of it like a cloth 110 00:07:08,730 --> 00:07:12,570 which wants to like wrap itself around, you know, a shape. 111 00:07:12,970 --> 00:07:17,130 And I mean a cloth can also occupy like energy, like minima. 112 00:07:17,210 --> 00:07:19,730 So it's almost like the most stabilized state is the one that 113 00:07:19,730 --> 00:07:24,890 it occupies. So like the protein would occupy. So that's the 114 00:07:24,890 --> 00:07:28,530 kind of, that's what IDPs are. But globular proteins would be more 115 00:07:28,530 --> 00:07:31,810 like, I mean, we talk about the origami. You know, they have 116 00:07:31,810 --> 00:07:35,410 like fixed, like a fixed shape or a fixed structure. So, so that 117 00:07:35,410 --> 00:07:37,570 could be like a very general comparison, I would say. 118 00:07:37,650 --> 00:07:41,410 And how many, I mean, is this like there are three disordered proteins 119 00:07:41,410 --> 00:07:45,290 in the world? How prevalent are disordered proteins or disordered 120 00:07:45,290 --> 00:07:45,810 regions? 121 00:07:47,170 --> 00:07:49,890 I would say like research, like many researchers have shown 122 00:07:49,890 --> 00:07:54,850 that at least more than like about 80%, there would be at least 123 00:07:54,850 --> 00:07:59,210 one disordered region. And one has to think about disorder in terms 124 00:07:59,210 --> 00:08:02,210 of the length, the threshold. Like, what is the threshold? Because 125 00:08:02,370 --> 00:08:05,410 there could be a protein that could have ordered regions and disordered 126 00:08:05,410 --> 00:08:10,990 regions. And how do you really define disorder? Like there are proteins 127 00:08:10,990 --> 00:08:13,110 that have completely disordered regions, some of Them 128 00:08:13,110 --> 00:08:15,430 have certain domains that are disordered and some of them that 129 00:08:15,430 --> 00:08:17,790 are ordered and. Yeah,. 130 00:08:18,270 --> 00:08:21,910 And so I think that's, that is a startling statistic for people 131 00:08:21,910 --> 00:08:26,790 because the viewpoint that we have is that most proteins are structured 132 00:08:26,790 --> 00:08:31,150 and maybe they have little bits of floppy regions. But if 80% 133 00:08:31,310 --> 00:08:35,390 of proteins potentially have some disordered regions within them, 134 00:08:35,550 --> 00:08:40,700 then this is the majority of the proteome. And, and I mean, is 135 00:08:40,700 --> 00:08:45,340 it, is it grand to say that some very large percent of protein 136 00:08:45,340 --> 00:08:50,340 function on a proteome scale is actually driven by disordered 137 00:08:50,340 --> 00:08:51,900 regions or disordered proteins? 138 00:08:52,860 --> 00:08:56,180 Of course, yes. I, I, I get very excited by this idea because, 139 00:08:56,180 --> 00:08:59,820 I mean, I think of the cell as a finite volume and think of, like, 140 00:08:59,820 --> 00:09:02,700 when people talk about proteins, they just talk about abundances. 141 00:09:02,700 --> 00:09:06,300 Okay, Proteins have increased, decrease, like what happens. But 142 00:09:06,460 --> 00:09:09,980 if a protein is disordered, imagine, like, it can take so many 143 00:09:09,980 --> 00:09:13,820 different shapes and interact with so many different of its surroundings. 144 00:09:13,820 --> 00:09:17,900 So in that crowded environment of the cell, I feel, I mean, this 145 00:09:17,900 --> 00:09:25,180 disorder is giving the protein the kind of the agency to do different 146 00:09:25,180 --> 00:09:29,140 things in that finite space. And that to me, like, it just kind 147 00:09:29,140 --> 00:09:32,940 of, it's so exciting because also it's so true because it's physics 148 00:09:33,420 --> 00:09:34,660 that it just makes sense. 149 00:09:35,210 --> 00:09:39,690 Yeah. So, I mean, this really is, I mean, as you're describing 150 00:09:39,690 --> 00:09:45,450 this, what's running around in my head is that the disordered regions 151 00:09:45,930 --> 00:09:52,650 are how proteins have functions. Whereas again, our canonical 152 00:09:52,650 --> 00:09:55,890 view back in the day was that, you know, proteins like trypsin, 153 00:09:55,890 --> 00:09:59,010 they have function because they orient these specific amino 154 00:09:59,010 --> 00:10:03,130 acids in the specific shape that allows an enzymatic function 155 00:10:03,130 --> 00:10:06,130 to occur. And it's always that way. And maybe you talk a little 156 00:10:06,130 --> 00:10:09,390 bit about the lock and key mechanism, the Jacob Mono sort of 157 00:10:09,390 --> 00:10:14,870 model, but really thinking about proteins as these dynamic entities 158 00:10:15,110 --> 00:10:18,470 as opposed to these static entities. So it's not like they are, 159 00:10:18,710 --> 00:10:22,829 you know, they are these rigid Legos that have, you know, move a 160 00:10:22,829 --> 00:10:27,350 little bit. They are really wobbly, floppy things that, and that 161 00:10:27,350 --> 00:10:30,070 wobbly floppiness is how they do their job. 162 00:10:30,550 --> 00:10:34,190 Exactly. Yeah, that is it. And it also makes sense because, like, 163 00:10:34,190 --> 00:10:36,950 I talk about the crowded environment of the cell, but also 164 00:10:36,950 --> 00:10:41,290 in terms of space, energy utilization, like biology is incredibly 165 00:10:41,290 --> 00:10:47,410 efficient. So if something was given, could take different shapes 166 00:10:47,410 --> 00:10:49,730 and different times, they could come together and catalyze 167 00:10:49,730 --> 00:10:52,090 a reaction and then just go back to a different shape and do 168 00:10:52,090 --> 00:10:52,690 something else. 169 00:10:53,970 --> 00:10:57,970 So one protein having many different jobs as a function. And 170 00:10:57,970 --> 00:11:01,170 we had Kathryn Lilly on the show, and she was talking about how 171 00:11:01,170 --> 00:11:03,650 proteins can do different things in different parts of the 172 00:11:03,650 --> 00:11:08,070 cell. And do you think that maybe part of the way they're able 173 00:11:08,070 --> 00:11:11,630 to do that is that they actually have different shapes when 174 00:11:11,630 --> 00:11:13,190 they're in different places in the cell? 175 00:11:14,230 --> 00:11:18,710 Yes. And I mean, people have studied one aspect like allostery 176 00:11:18,710 --> 00:11:21,430 for a long time. I mean, there are still aspects of it that we need 177 00:11:21,430 --> 00:11:24,830 to understand. But it tells you like how something, if it's bound 178 00:11:24,830 --> 00:11:28,590 to one side, it can change the shape on the other side. And so there 179 00:11:28,590 --> 00:11:32,940 is like, there is, it happens like proteins can change like this, 180 00:11:32,940 --> 00:11:38,220 this kind of interaction. So a large, like a protein can have this 181 00:11:38,220 --> 00:11:40,700 globally as well to, you know, to do different functions. 182 00:11:41,100 --> 00:11:44,900 Wow. So it sounds like intrinsically disordered regions, 183 00:11:44,900 --> 00:11:48,580 intrinsically disordered proteins are just critical to how 184 00:11:48,580 --> 00:11:52,780 cells work. Tell me a little bit about the other side. About. 185 00:11:54,140 --> 00:11:57,940 We, you know, we talk about tau, alpha, synuclein, some of these 186 00:11:57,940 --> 00:12:01,540 other proteins as being intrinsically disordered proteins 187 00:12:01,540 --> 00:12:03,560 or prote proteins with intrinsically disordered regions. 188 00:12:05,000 --> 00:12:10,360 When do intrinsically disordered proteins go bad and become 189 00:12:10,360 --> 00:12:11,400 drivers of disease? 190 00:12:12,440 --> 00:12:15,360 So that's a very interesting question and something we want to 191 00:12:15,360 --> 00:12:20,200 solve. We don't know when they go bad or how. We know how to some 192 00:12:20,200 --> 00:12:24,760 extent, but we don't know what drives them. So to give context, 193 00:12:25,320 --> 00:12:31,400 proteins that are implicated in Alzheimer's hallmarks and Parkinson's, 194 00:12:31,480 --> 00:12:35,660 most neurodegenerative diseases, they are disordered, more 195 00:12:35,660 --> 00:12:41,860 like fully disordered. And they aggregate. And these are the 196 00:12:41,860 --> 00:12:45,300 hallmarks. And people who have Alzheimer's in the brains. 197 00:12:45,620 --> 00:12:49,380 And when they aggregate, they form these giant plaques that in 198 00:12:49,380 --> 00:12:53,300 themselves, mechanically can get in the way of cellular processing. 199 00:12:53,620 --> 00:12:57,540 Exactly. So you can think of, again, look at the concept of disorder. 200 00:12:57,620 --> 00:13:00,300 If it is taking different shapes to interact with the partners, 201 00:13:00,300 --> 00:13:04,020 it can also take different shapes to misinteract or just have 202 00:13:04,020 --> 00:13:09,100 the wrong interaction and be sucked into that and just get caught. 203 00:13:09,340 --> 00:13:12,180 And how I like to think of it is like a black hole. Like if you 204 00:13:12,180 --> 00:13:15,700 have some, some like a little seed, it'll just keep, you know, 205 00:13:15,700 --> 00:13:19,260 keep like thermodynamically, it's just going to. It's just going 206 00:13:19,260 --> 00:13:21,420 to grow into this larger plaque. And that's what's seen in 207 00:13:21,420 --> 00:13:24,660 a lot of CO pathologies as well, where you have alpha, synucle 208 00:13:24,660 --> 00:13:29,750 and tau altogether like their CO pathologies and we still don't 209 00:13:29,750 --> 00:13:33,390 know the answers, like how they land there. Is it because the 210 00:13:33,390 --> 00:13:38,630 cells, proteostatic machinery, it got disrupted, which does happen 211 00:13:38,630 --> 00:13:42,350 with age, but maybe some cells are more resilient. So there are 212 00:13:42,350 --> 00:13:45,710 lots of factors that can contribute to this what we do not 213 00:13:45,710 --> 00:13:51,190 know is that what leads to this disordered state, to this aggregate 214 00:13:51,190 --> 00:13:57,360 state, what's the path? If a single, like if this monomeric protein 215 00:13:57,360 --> 00:14:01,200 can occupy thousands of ensembles, thousands of thousands 216 00:14:01,200 --> 00:14:05,280 of structures in an ensemble, which of these subset would lead 217 00:14:05,280 --> 00:14:09,120 to the aggregated state versus which of the subset will keep it 218 00:14:09,120 --> 00:14:12,880 soluble and keep people healthy? 219 00:14:13,360 --> 00:14:17,920 And so you mentioned there's this gap in understanding. Why is 220 00:14:17,920 --> 00:14:21,920 there a gap in understanding? You hear people talk about intrinsically 221 00:14:21,920 --> 00:14:26,260 disordered proteins being hard to study. Why are, and you hear about 222 00:14:26,260 --> 00:14:30,620 them being hard to drug. Why are they hard to study? Why are they 223 00:14:30,620 --> 00:14:31,260 hard to drug? 224 00:14:32,700 --> 00:14:38,100 It's because they're hard to capture experimentally. You can take 225 00:14:38,100 --> 00:14:44,740 a snapshot, but if a protein is changing its shape very, very 226 00:14:44,740 --> 00:14:47,620 fast, nanosecond, how do you capture that? How do you capture 227 00:14:47,620 --> 00:14:50,980 that scale? We need very sophisticated techniques to capture 228 00:14:50,980 --> 00:14:55,100 that scale. And not only like a couple of times, but across. And 229 00:14:55,100 --> 00:14:58,940 then which of those are relevant for disease? Which of those 230 00:14:58,940 --> 00:15:02,980 are druggable? Because it could be that of those many states, 231 00:15:03,140 --> 00:15:07,819 a few of them are forming a pocket that a drug can bind to. But 232 00:15:07,819 --> 00:15:11,700 that's also happening at a very small timescale. So I think 233 00:15:11,700 --> 00:15:16,340 it's about techniques that can help us study those proteins at the 234 00:15:16,340 --> 00:15:21,260 same time having that in a time resolved manner so that we can 235 00:15:21,260 --> 00:15:24,540 capture all of these snapshots, you know, to, to make 236 00:15:24,540 --> 00:15:27,140 a movie out of it, to understand what's really happening, 237 00:15:27,140 --> 00:15:30,940 like the dynamic structure of these, dynamic dynamism of these 238 00:15:30,940 --> 00:15:31,460 proteins. 239 00:15:31,940 --> 00:15:36,660 So I think maybe part of what is forming in my head as you're describing 240 00:15:36,660 --> 00:15:44,580 this is that for right now, what we have in terms of technologies, 241 00:15:44,740 --> 00:15:50,560 we're really good at taking single time point pictures and we're 242 00:15:50,560 --> 00:15:55,840 okay at taking movies so long as the frame rate of that movie is 243 00:15:55,840 --> 00:16:02,880 pretty slow. But then if we wanted to collect movies on the nanosecond 244 00:16:03,520 --> 00:16:09,160 timescale, we like the tools that we have available to us to look 245 00:16:09,160 --> 00:16:11,600 at things on that timescale are really limited. 246 00:16:12,720 --> 00:16:18,330 Yes, I mean, we've been using a lot of computation, like simulation. 247 00:16:20,650 --> 00:16:23,650 Then the question always is that which of these structures are 248 00:16:23,650 --> 00:16:28,730 experimentally relevant. What some researchers have done, and Michele, 249 00:16:29,930 --> 00:16:33,450 my PhD advisor also did, was like using experimental restraints 250 00:16:33,610 --> 00:16:37,050 to restrain these simulations to tell these are the ground truths. 251 00:16:37,290 --> 00:16:43,070 And then you kind of of bias those, not biased, but you kind of 252 00:16:43,070 --> 00:16:45,830 restrain the simulations to see what is happening. So those are 253 00:16:45,830 --> 00:16:50,310 ways in which you can study those, like some of the ways in which 254 00:16:50,310 --> 00:16:52,550 you can study these dynamic structures. 255 00:16:52,550 --> 00:16:55,550 Well, and that's and you know, you mentioned physics, that kind 256 00:16:55,550 --> 00:16:59,270 of approach of well, I can't measure the phenomenon itself, but 257 00:16:59,270 --> 00:17:03,310 I can measure products of the phenomenon or snapshots of the phenomenon 258 00:17:03,870 --> 00:17:07,230 is very common. For instance, we think about these large collider 259 00:17:07,230 --> 00:17:11,090 experiments where, you know, you can't actually observe the particle, 260 00:17:11,090 --> 00:17:13,970 but you can observe the decay products of the particle. And then 261 00:17:14,130 --> 00:17:17,690 that then feeds in and helps train the model to say, okay, well 262 00:17:17,690 --> 00:17:20,610 how, where could that have come from? It must have come from 263 00:17:20,610 --> 00:17:22,890 something that looked like this as opposed to something that 264 00:17:22,890 --> 00:17:23,490 looked like that. 265 00:17:24,290 --> 00:17:29,010 Exactly, yes. So we need more data and we need to know to some 266 00:17:29,090 --> 00:17:32,330 like, what does that data look like? And then really use experiments 267 00:17:32,330 --> 00:17:36,170 and computation to kind of predict to form like, okay, these 268 00:17:36,170 --> 00:17:38,450 are the experiments, these are some of the snapshots we've taken. 269 00:17:39,330 --> 00:17:41,810 This is what it looks like in the final stage. This is what it 270 00:17:41,810 --> 00:17:45,450 looks like initially and maybe between healthy disease, between 271 00:17:45,450 --> 00:17:48,370 different kinds of diseases, the same protein causes like tau. 272 00:17:48,690 --> 00:17:52,570 And then put all of this information together, grounded by 273 00:17:52,570 --> 00:17:57,530 rules of physics and chemistry, and then see what happens. 274 00:17:57,530 --> 00:18:01,850 And this demand experiments, computation and also computation 275 00:18:01,850 --> 00:18:08,320 at a speed that is like you cannot run an experiment on for many, 276 00:18:08,320 --> 00:18:10,640 many, many days or months or something. So. 277 00:18:11,040 --> 00:18:15,240 Yes, and so tell me today, what are the tools? You know, your 278 00:18:15,240 --> 00:18:17,680 lab also does, has a tremendous amount of experience with 279 00:18:17,680 --> 00:18:21,160 mass spectrometry. And what, what's the toolbox that people are 280 00:18:21,160 --> 00:18:24,240 working with experimentally today to, to study intrinsically 281 00:18:24,240 --> 00:18:25,200 disordered proteins? 282 00:18:26,160 --> 00:18:31,090 So some of the. So I can start with how people studied globular 283 00:18:31,090 --> 00:18:34,050 proteins. Like people did a lot of X ray diffraction, people 284 00:18:34,050 --> 00:18:37,290 did X ray diffraction. And if you look at pdb, there's a lot of 285 00:18:37,450 --> 00:18:41,050 crystallography data which is great, which gives you electron densities. 286 00:18:41,370 --> 00:18:45,090 And then when people missed out those electron densities, they 287 00:18:45,090 --> 00:18:47,930 were like they couldn't solve the structure. So all of those regions 288 00:18:47,930 --> 00:18:51,490 are missing. That means that those regions are dynamic. And there 289 00:18:51,490 --> 00:18:54,530 are techniques like nuclear magnetic resonance that can capture 290 00:18:54,530 --> 00:19:00,660 that. There is small angle X ray scattering, which again is diffraction, 291 00:19:00,660 --> 00:19:05,580 but in solution at a small angle, which for a floppy protein, 292 00:19:05,660 --> 00:19:10,020 at those small angles, you can get the radius of gy, like the shape, 293 00:19:10,020 --> 00:19:12,820 the radius of gyration. And you can tell what this protein would 294 00:19:12,820 --> 00:19:18,860 look like. You can also look at, you can also use cryo em to again 295 00:19:19,020 --> 00:19:22,810 to capture many, many snapshots of it. Because once the 296 00:19:22,810 --> 00:19:25,570 protein is kind of frozen, like in different conformations, 297 00:19:25,570 --> 00:19:29,290 you can use those images to build on what this structure could 298 00:19:29,290 --> 00:19:29,730 look like. 299 00:19:29,890 --> 00:19:33,770 What the range might exist because you've literally locked it 300 00:19:33,770 --> 00:19:38,770 in place and so you're slowing it down. It's kind of like again, 301 00:19:38,770 --> 00:19:41,330 what I'm thinking about is people taking pictures with their 302 00:19:41,330 --> 00:19:45,330 camera and someone is running around in the background. You get 303 00:19:45,330 --> 00:19:49,250 this sort of blurry, smeary thing in your image. And so if you're 304 00:19:49,250 --> 00:19:52,760 not taking pictures at the right frame rate, you just get these 305 00:19:52,760 --> 00:19:54,920 blurry things, but at least you know it's in motion. 306 00:19:55,400 --> 00:19:56,520 Yes, exactly. 307 00:19:56,840 --> 00:20:00,760 And then with the cryo em you can literally stop it in its tracks 308 00:20:00,760 --> 00:20:04,360 and look at a wide variety of different shapes. 309 00:20:05,080 --> 00:20:08,880 That's true. Yeah. You can also use mass spectrometry and that's 310 00:20:08,880 --> 00:20:12,480 one of the techniques that I learned in Paula Picoti's lab at 311 00:20:12,480 --> 00:20:16,840 ET at Zurich, which was limited proteolysis, mass spec based 312 00:20:16,840 --> 00:20:20,200 proteomics, which is essentially looking at the exposed 313 00:20:20,280 --> 00:20:26,020 regions of you know, these different regions of these proteins, 314 00:20:26,820 --> 00:20:31,220 these disordered proteins. So that is also one of the other techniques 315 00:20:31,220 --> 00:20:31,940 that one can use. 316 00:20:32,180 --> 00:20:35,100 Yeah. So this is a technique that people are probably not familiar 317 00:20:35,100 --> 00:20:39,340 with. So maybe just say a little bit more about how people 318 00:20:39,340 --> 00:20:42,860 are used to shotgun mass spectrometry where you know, you 319 00:20:42,860 --> 00:20:46,180 digest everything and you denature the proteins first. But 320 00:20:46,180 --> 00:20:49,420 in the method you're describing, this is done in a very 321 00:20:49,420 --> 00:20:52,940 different way. Where can you maybe just tell us a little bit about 322 00:20:52,940 --> 00:20:56,860 how, how limited proteolysis actually helps you learn about protein 323 00:20:56,860 --> 00:20:57,420 structure? 324 00:20:57,900 --> 00:21:02,220 Yes. So there are certain non specific proteases like that are, 325 00:21:02,220 --> 00:21:05,979 that exist which can, which can have non specific cleavage sites. 326 00:21:05,979 --> 00:21:08,260 And one of them like, you know, if you use like proteinase 327 00:21:08,260 --> 00:21:12,660 K, it's going to cleave at non specific sites. So if a protein is 328 00:21:12,660 --> 00:21:15,660 folded in say like one structure, it's, it'll only have 329 00:21:15,660 --> 00:21:18,900 access to certain sites. But if it's folded in a different structure 330 00:21:18,900 --> 00:21:21,420 it's going to have access to different sites. And if something 331 00:21:21,420 --> 00:21:24,520 is bound down to it like a drug or a ligand, it's going to have 332 00:21:24,520 --> 00:21:28,680 again the accessible sites differ. So this like proteinase K 333 00:21:28,680 --> 00:21:31,720 can have like, it's limited proteolysis because it's going and 334 00:21:31,720 --> 00:21:35,360 activate like looking at non specific sites and then what you 335 00:21:35,360 --> 00:21:38,560 get are basically conformitypic peptides which essentially 336 00:21:38,560 --> 00:21:44,240 represent like a fingerprint of what, what the, what, what, what 337 00:21:44,240 --> 00:21:46,920 the different structures could like, what they could look like. 338 00:21:47,160 --> 00:21:50,840 So you can basically say that if there is a protein that exists 339 00:21:50,840 --> 00:21:55,620 in a couple of different structures in a dis, you can perform 340 00:21:55,620 --> 00:21:58,780 this method and see what could These different states look like 341 00:21:58,780 --> 00:22:02,460 in different patients and get like a fingerprint, a structural 342 00:22:02,460 --> 00:22:03,140 fingerprint. 343 00:22:03,300 --> 00:22:06,260 Yeah. So I mean, the way that I think about it is you essentially 344 00:22:06,260 --> 00:22:10,420 have this messy ball of yarn, which is your protein structure, 345 00:22:10,580 --> 00:22:13,820 and then you've got a set of scissors. And the scissors can only 346 00:22:13,820 --> 00:22:17,100 get to the little strands that are on the surface of that messy 347 00:22:17,100 --> 00:22:21,340 ball of yarn. And so if you see a cut in a row in a particular 348 00:22:21,340 --> 00:22:24,100 region that says, oh, okay, this must have been on the outside 349 00:22:24,100 --> 00:22:27,380 of the ball of yarn as opposed to buried in the middle of the ball 350 00:22:27,380 --> 00:22:31,900 of yarn. And the mass spec is really helping you see where the 351 00:22:31,900 --> 00:22:37,020 sites of the cuts were, where the scissors were able to act, and 352 00:22:37,100 --> 00:22:42,940 that you may see a range of sets of different answers come back. 353 00:22:43,020 --> 00:22:48,770 And the ratios and prevalences can shift when you drop a drug in 354 00:22:48,770 --> 00:22:51,690 or you change the ph or even when you introduce another protein 355 00:22:51,690 --> 00:22:52,290 potentially. 356 00:22:52,850 --> 00:22:56,890 Yes, absolutely. That's a really good example, really good 357 00:22:56,890 --> 00:22:58,050 way of looking at it. 358 00:22:58,610 --> 00:23:03,570 For our readers who want to learn about this space. Can you maybe 359 00:23:03,570 --> 00:23:10,610 give me an example of the archetypal IDP that has multiple 360 00:23:10,610 --> 00:23:15,140 different structures that act in different ways, drives different 361 00:23:15,380 --> 00:23:19,620 biological functions and sort of what your favorite example paper 362 00:23:19,620 --> 00:23:23,300 is from talking about that protein? 363 00:23:24,340 --> 00:23:27,820 Yeah, so I think I would have different proteins depending on the 364 00:23:27,820 --> 00:23:33,220 context, what we study as well. So I would start with the paper 365 00:23:33,220 --> 00:23:37,220 that inspired me to study IDPs was this interaction between C. Myc 366 00:23:37,220 --> 00:23:40,660 and Max. They're oncogenic proteins and they are completely 367 00:23:40,660 --> 00:23:43,930 disordered on their own, but they come together and assume an 368 00:23:44,320 --> 00:23:47,720 structure and that, that. So, and there, there can be small molecules 369 00:23:47,720 --> 00:23:51,440 that can, that can disrupt this and that's. And, and, and it's 370 00:23:51,440 --> 00:23:54,800 been super hard to even study those interactions. So that's, that's 371 00:23:54,800 --> 00:23:58,160 one of the, that's one of those two, two proteins that, that, 372 00:23:58,160 --> 00:24:02,240 that, you know, I would, that though that's one. The second is 373 00:24:02,880 --> 00:24:07,240 P53MDM2 interaction. And it's very interesting because, you know, 374 00:24:07,240 --> 00:24:11,360 I meet some people who say like P53 has been studied for a long, 375 00:24:11,360 --> 00:24:14,000 long time. We know everything. I've even met people who are like, 376 00:24:14,000 --> 00:24:18,320 oh, this person, you know, like is the P53 person. But they 377 00:24:18,320 --> 00:24:21,680 did not study disorder. They did they like, you know, they, they 378 00:24:21,680 --> 00:24:24,760 did not study that. P53 has these, it's not completely disordered, 379 00:24:24,760 --> 00:24:27,920 but it has both ordered and disordered domains and depending 380 00:24:27,920 --> 00:24:31,680 on that it engages with its targets and causes. Like, has different 381 00:24:31,680 --> 00:24:36,080 functions and it is, it's almost like sitting in a hub and 382 00:24:36,080 --> 00:24:38,990 Then you have like these network of protein interactions and 383 00:24:38,990 --> 00:24:43,510 I, and still we haven't been able to understand all of those interactions. 384 00:24:43,830 --> 00:24:46,830 So if someone really, really is excited about like, because there's 385 00:24:46,830 --> 00:24:50,390 so much information about this, this, this protein set that, 386 00:24:50,390 --> 00:24:54,070 that, that I would, I would encourage them to read. And the other 387 00:24:54,070 --> 00:24:57,470 protein which is my favorite protein is tau for, for reason that 388 00:24:57,470 --> 00:25:03,430 I study it. But I think it's a, it's an, a challenging, enigmatic, 389 00:25:03,510 --> 00:25:07,750 fun protein to work with because it also causes like disease, 390 00:25:07,750 --> 00:25:11,370 but there are also functional aspects of it. Understand. So this 391 00:25:11,370 --> 00:25:14,210 is like the more challenging aspect that people may not be able 392 00:25:14,210 --> 00:25:17,490 to find more, but that's where we are sitting right now to understand 393 00:25:17,490 --> 00:25:18,050 it better. 394 00:25:18,850 --> 00:25:21,970 That's very interesting. And with P53 people often talk about 395 00:25:21,970 --> 00:25:26,290 how it has two very different functions. One is DNA damage sensing 396 00:25:26,290 --> 00:25:31,090 and the other is DNA damage response. And is it believed that 397 00:25:31,090 --> 00:25:35,970 maybe that split in its behavior and function is actually 398 00:25:36,050 --> 00:25:38,210 related to its IDP properties? 399 00:25:39,440 --> 00:25:40,200 Maybe. Yes. 400 00:25:40,200 --> 00:25:44,920 Yeah. Wow, that would be amazing. Priyanka, I wanted to ask 401 00:25:44,920 --> 00:25:51,080 you about one of your papers from 2016, this really beautiful 402 00:25:51,080 --> 00:25:54,720 work on fragment based method for creating small molecule libraries 403 00:25:54,880 --> 00:25:59,040 for developing therapeutics for intrinsically disordered proteins. 404 00:26:00,560 --> 00:26:03,480 Maybe first tell us just a little bit about that work and then 405 00:26:03,480 --> 00:26:06,680 what I'm curious about is you published that paper maybe a decade 406 00:26:06,680 --> 00:26:11,110 ago now. If you were to redo that study or extend that study today, 407 00:26:11,270 --> 00:26:12,790 how would it look different? 408 00:26:13,670 --> 00:26:17,670 Yeah, so that's the paper that really got me excited and that's 409 00:26:17,670 --> 00:26:24,190 the work that I did during my PhD at Cambridge. And so what we've 410 00:26:24,190 --> 00:26:29,910 showed is that because there are no druggable pockets like normal 411 00:26:29,990 --> 00:26:34,390 globular proteins and IDPs and they have pretty much extended structures, 412 00:26:34,630 --> 00:26:38,430 how can we design small molecule drugs to bind to those and 413 00:26:38,430 --> 00:26:43,170 change the course of aggregation? So in this paper, basically 414 00:26:43,170 --> 00:26:47,810 what I show is that you can take different fragments of known 415 00:26:47,890 --> 00:26:54,330 binders and then combine them in novel ways to make better binders 416 00:26:54,330 --> 00:26:58,410 that can slow down the aggregation of these IDPs, which 417 00:26:58,410 --> 00:27:02,210 in particular in my case what I've shown it is an amyloid beta. 418 00:27:04,370 --> 00:27:08,890 And I think there is something in that which is which, which we 419 00:27:08,890 --> 00:27:11,130 still need to understand, which is like what are the rules? 420 00:27:11,130 --> 00:27:14,650 What are the rules of these small molecule, you know, these, 421 00:27:14,650 --> 00:27:17,610 these drugs. Because if you can break them into fragments and 422 00:27:17,610 --> 00:27:20,290 then recombine them and make something better, then maybe there 423 00:27:20,290 --> 00:27:22,850 is a rule to make it, to combine it and make it better. And 424 00:27:22,850 --> 00:27:25,850 that's why I say like chemistry based AI Maybe we can find 425 00:27:25,850 --> 00:27:29,450 those rules now. And it's not just the rules in these drug molecules, 426 00:27:29,450 --> 00:27:34,420 but also on the IDP side because this is, is an IDP which 427 00:27:34,420 --> 00:27:38,380 is completely disordered and having, giving all these large surface 428 00:27:38,380 --> 00:27:41,620 areas, maybe there are rules in the arrangement of these amino 429 00:27:41,620 --> 00:27:45,100 acids, in the way the exposed, you know, the solvent axis is there. 430 00:27:45,340 --> 00:27:49,219 So together I think like now using physics and chemistry based 431 00:27:49,219 --> 00:27:53,780 AI, so like more advanced, like getting more measurements, we 432 00:27:53,780 --> 00:27:56,620 can, we can, we can answer this question better to get these 433 00:27:56,620 --> 00:28:00,380 drugs. But what's even more fascinating is, and what, what basically 434 00:28:00,380 --> 00:28:05,130 inspired my research from that paper and that study was that after 435 00:28:05,130 --> 00:28:09,690 that work I saw like in my library of small molecules, there 436 00:28:09,690 --> 00:28:15,850 were molecules that looked like ATP, gluc, small metabolites. 437 00:28:15,850 --> 00:28:19,210 And I asked the question that if synthetic chemists can design 438 00:28:19,290 --> 00:28:24,250 drugs, then nature over the course of evolution must have designed 439 00:28:24,410 --> 00:28:27,610 small molecules that keep proteins stable inside the cell. 440 00:28:27,690 --> 00:28:31,130 And that's when I wanted to work into environment and metabolites 441 00:28:31,130 --> 00:28:35,060 to know that, okay, how does, how does this really work? And that 442 00:28:35,060 --> 00:28:37,620 just makes so much sense to me. It's just that we need more data 443 00:28:37,620 --> 00:28:40,380 and more mechanistic, you know, to, to actually understand 444 00:28:40,380 --> 00:28:43,580 that. So, so that's, that's where my journey began. And I feel 445 00:28:43,580 --> 00:28:45,980 we can do so much more based off that. 446 00:28:46,860 --> 00:28:49,020 You know, it's interesting you saying this. I had a conversation 447 00:28:49,020 --> 00:28:54,660 with my graduate advisor, David Eisenberg about, about intrinsically 448 00:28:54,660 --> 00:28:57,940 disordered proteins and aggregation and, and what he was 449 00:28:57,940 --> 00:29:01,150 saying. I, I honestly thought he was kind of nuts when he was describing 450 00:29:01,150 --> 00:29:04,830 this because he was saying, oh well, you know, I think part of what 451 00:29:04,830 --> 00:29:08,150 is driving this aggregation is actually not protein protein interactions, 452 00:29:08,150 --> 00:29:12,870 but potentially protein nucleotide interactions. I was like, 453 00:29:14,230 --> 00:29:19,270 that is not something that I ever thought about as exogenous factors, 454 00:29:19,270 --> 00:29:24,150 either RNA or even, you know, nucleosides, nucleotides interacting 455 00:29:24,150 --> 00:29:27,350 with proteins and then causing them to behave in a completely different 456 00:29:27,350 --> 00:29:31,490 way. But that sounds, based on what you're saying about adp, et 457 00:29:31,490 --> 00:29:34,610 cetera, right in line with. 458 00:29:35,970 --> 00:29:39,490 Absolutely. And I can go an hour talking about those interactions 459 00:29:39,490 --> 00:29:42,890 because there have been super like studies by others that have 460 00:29:42,890 --> 00:29:47,370 shown that ATP, they can form these, you know, they can face separate 461 00:29:47,370 --> 00:29:51,290 and then they can cause and trigger. But we can go, we can talk 462 00:29:51,290 --> 00:29:52,210 a lot about that. 463 00:29:53,010 --> 00:29:58,120 Well, no, that's great. Yeah. And so what is your hope? So it sounds 464 00:29:58,120 --> 00:30:00,960 like that's the set of tools, that's the tools that we have today. 465 00:30:01,600 --> 00:30:07,360 And if we are wildly successful in understanding intrinsically 466 00:30:07,360 --> 00:30:11,160 disordered proteins, what does that do for us? How does that help 467 00:30:11,160 --> 00:30:11,440 us? 468 00:30:12,480 --> 00:30:17,480 I mean, a large number of diseases are caused, like the proteins 469 00:30:17,480 --> 00:30:19,720 that are implicated are intrinsically disordered. So we're 470 00:30:19,720 --> 00:30:22,480 talking about disease. When we're talking about impact, we're 471 00:30:22,480 --> 00:30:25,760 talking about disease here. So, I mean, I'm interested in neurodegenerative 472 00:30:25,760 --> 00:30:32,980 diseases. And in that, like, what a wild success for me would 473 00:30:32,980 --> 00:30:36,980 look like is that if I could look at these proteins and then really 474 00:30:36,980 --> 00:30:40,300 follow their path and understand that why do they fold 475 00:30:40,380 --> 00:30:45,220 or misfold in one person under certain conditions and not in the 476 00:30:45,220 --> 00:30:49,620 other? So for that, capture the path of those proteins, look 477 00:30:49,620 --> 00:30:54,590 at it from the different states of it and really distinguish 478 00:30:54,590 --> 00:30:58,110 between healthy versus disease states, because that's going to be 479 00:30:58,110 --> 00:31:01,750 essential. And that's actually important for drugs to work as well, 480 00:31:01,910 --> 00:31:05,190 because a large number of drugs that are failing and, you know, 481 00:31:05,190 --> 00:31:09,150 like, that are not successful in every patient population is because 482 00:31:09,150 --> 00:31:12,510 people's proteins, like these shapes and aggregates, they might 483 00:31:12,510 --> 00:31:15,550 be different. And it might be that the drugs we are making are 484 00:31:15,550 --> 00:31:18,550 just made for one kind of, you know, the yarn, the ball, the yarn 485 00:31:18,550 --> 00:31:21,310 that you're making. But there could be that maybe some yarn is 486 00:31:21,310 --> 00:31:23,980 like, maybe has a little, like, I don't know, like a little. 487 00:31:25,100 --> 00:31:26,300 Has a divot in it, for instance. 488 00:31:26,300 --> 00:31:29,900 Yeah, exactly. Something so, so, so, so that could be. And I think 489 00:31:30,380 --> 00:31:36,300 if we could capture those, like what these range of, I mean, 490 00:31:36,620 --> 00:31:39,540 you know, different proteoforms, like, if I can use that 491 00:31:39,540 --> 00:31:42,820 word now, like, you know, if what they could look like, then we 492 00:31:42,820 --> 00:31:45,980 can really distinguish that what are the healthy ones versus 493 00:31:45,980 --> 00:31:49,100 disease ones. And then we can make effective drugs that would actually 494 00:31:49,180 --> 00:31:53,760 work for most people rather than just a certain set of people. 495 00:31:54,160 --> 00:31:58,240 No, that makes a lot of sense. And that's a good segue to talk about 496 00:31:58,240 --> 00:32:06,600 proteforms. So we've talked about how proteins have a wide range 497 00:32:06,600 --> 00:32:09,960 of shapes and structures. We've also in the past mentioned 498 00:32:09,960 --> 00:32:13,200 proteoforms and how they can be decorated and have phosphorylations 499 00:32:13,200 --> 00:32:18,320 and methylations and truncations, et cetera. Talk to me 500 00:32:18,320 --> 00:32:21,880 a little bit about your personal beliefs in the connection 501 00:32:21,880 --> 00:32:26,040 between proteoforms and intrinsically disordered protein 502 00:32:26,280 --> 00:32:30,640 ensembles. And what do you believe the connection is there between 503 00:32:30,640 --> 00:32:31,160 the two? 504 00:32:31,880 --> 00:32:34,600 Yeah, so I'll take my favorite example, which is tau, which I'm 505 00:32:34,600 --> 00:32:40,120 also working on, which is like, there's this one protein that 506 00:32:40,280 --> 00:32:44,560 misfolds and causes a range of tauopathies. It aggregates in different 507 00:32:44,560 --> 00:32:47,760 parts of the brain, causing different diseases and all progress 508 00:32:47,760 --> 00:32:50,620 at a different rate. In some people very fast and some people 509 00:32:50,620 --> 00:32:53,700 very slow. It causes different kinds of dementia. It's the same 510 00:32:53,700 --> 00:32:58,740 protein. And what I think is that it just meets different environments. 511 00:32:58,900 --> 00:33:02,780 Of course there could be some genetics, maybe not in tau, but in 512 00:33:02,780 --> 00:33:06,140 the surrounding environment of the cell. And which, which deems 513 00:33:06,140 --> 00:33:11,700 like either resilience to the cell or you know, disruption. But, 514 00:33:11,780 --> 00:33:17,570 but, but so that's how I define the path and I. And when the 515 00:33:17,570 --> 00:33:21,970 cell's environment is not favorable, that is contributing to 516 00:33:21,970 --> 00:33:24,730 this protein getting, occupying these different ensembles 517 00:33:24,810 --> 00:33:29,290 that are maybe more sticky, that kind of interact more with the 518 00:33:29,370 --> 00:33:33,290 surrounding regions and that just causes the cell to die or more 519 00:33:33,290 --> 00:33:36,290 disruption. And maybe there are other confirmations that are 520 00:33:36,290 --> 00:33:39,650 not so much that are, you know, like that. I mean, think of 521 00:33:39,650 --> 00:33:42,890 it like a person walking down a room and kind of getting and talking 522 00:33:42,890 --> 00:33:45,730 to different kinds of people and kind of, you know, maybe sticking 523 00:33:45,730 --> 00:33:50,190 to a crowd, but other crowd. So I think that's how these disordered 524 00:33:50,190 --> 00:33:53,470 proteins are also behaving inside the cell. And depending on 525 00:33:53,470 --> 00:33:56,950 what they are interacting with and where they are sitting and aggregating 526 00:33:56,950 --> 00:34:02,190 and growing into these structures can help us tell us tell 527 00:34:02,190 --> 00:34:06,110 what is disease and not. And I think we need both kinds of approaches, 528 00:34:06,110 --> 00:34:10,870 which is both fundamental where we are engineering these hypothesis 529 00:34:10,870 --> 00:34:14,670 driven and at the same time from the patients where we are collecting 530 00:34:14,670 --> 00:34:17,670 a lot of data samples and then looking what these proteins look 531 00:34:17,670 --> 00:34:21,290 like and then kind seeing that, okay, can we ask this question 532 00:34:21,290 --> 00:34:25,010 and can we kind of see what the outcomes would be? So I think 533 00:34:25,410 --> 00:34:25,970 that is. 534 00:34:26,210 --> 00:34:29,210 Sort of going both forwards and backwards of saying, all right, 535 00:34:29,210 --> 00:34:33,370 if we poke at the protein in this way, or we construct a triple 536 00:34:33,370 --> 00:34:37,450 phosphorylated form, what does it look like? And then going from 537 00:34:37,450 --> 00:34:40,970 the patient side and saying, all right, what are the set of flavors 538 00:34:40,970 --> 00:34:44,410 of proteins, of variants of proteins that exist and what is their 539 00:34:44,410 --> 00:34:47,940 phenotypic behavior and consequence and trying to meet in 540 00:34:47,940 --> 00:34:52,340 the middle between that ground up very mechanistic view and that 541 00:34:52,340 --> 00:34:54,700 more clinical translational perspective. 542 00:34:55,180 --> 00:34:57,740 Exactly. You said the right word, which is mechanistic view. 543 00:34:57,740 --> 00:35:01,980 And that's what we need. We need the mechanism and the data to 544 00:35:01,980 --> 00:35:03,020 kind of converge. 545 00:35:03,660 --> 00:35:08,100 That makes a lot of sense. So carrying on our theme of just understanding 546 00:35:08,100 --> 00:35:11,860 a little bit more about proteoforms, maybe a little bit of 547 00:35:11,860 --> 00:35:16,970 a cause and effect question for you. Do you believe that a proteoform 548 00:35:16,970 --> 00:35:23,650 identity, so its set of PTMs and truncations, et cetera, drives 549 00:35:23,650 --> 00:35:29,569 IDP structure? Or do you believe that the IDP structure drives 550 00:35:29,569 --> 00:35:32,130 the formation of different proteoforms. 551 00:35:34,130 --> 00:35:37,650 That's a very, very interesting question. And I would 552 00:35:37,650 --> 00:35:44,170 think of it both ways. So. So you know, when a protein is synthesized 553 00:35:44,170 --> 00:35:48,050 like after translation, it's also like co folding and it's. There 554 00:35:48,050 --> 00:35:50,690 are lots of things that are happening to it. So if you think 555 00:35:50,690 --> 00:35:54,370 of it that way, then whatever is happening to the protein could 556 00:35:54,370 --> 00:36:00,530 drive its different proteoforms. So it's like it's occupying 557 00:36:00,530 --> 00:36:04,650 many, many ensemble, like many, many different states. But 558 00:36:04,650 --> 00:36:07,770 then the one that is most stabilized is the one that is the 559 00:36:07,770 --> 00:36:10,930 proteoform in that given. In that given. So it's basically trying 560 00:36:11,390 --> 00:36:14,630 that energy minima. And it's basic. It's the moment it finds it, 561 00:36:14,630 --> 00:36:18,110 it becomes that proteoform. And that proteoform could tell us 562 00:36:18,110 --> 00:36:24,390 whether it's disease or not. Maybe. So that's one way of thinking 563 00:36:24,390 --> 00:36:32,350 about it. The other is you might have proteoforms that can trigger 564 00:36:32,750 --> 00:36:38,380 other idps to misfold or fold differently. Like you could have 565 00:36:38,380 --> 00:36:42,380 like a seed which, a nucleation, which can seed like nucleation 566 00:36:42,780 --> 00:36:48,460 and maybe change the other proteoforms to, you know, change 567 00:36:48,460 --> 00:36:50,460 their shape and then settle into something else. 568 00:36:52,940 --> 00:36:55,660 So I think I just want to summarize a little bit. It sounds 569 00:36:55,660 --> 00:36:59,580 like what you're saying is it goes both directions that and it 570 00:36:59,580 --> 00:37:04,540 goes as a network effect. So that a particular protein inhabiting 571 00:37:04,540 --> 00:37:08,460 one of a series of proteoforms or a set of proteoforms could drive 572 00:37:09,060 --> 00:37:12,580 differential IDP behavior in its friends and neighbors. And then 573 00:37:12,580 --> 00:37:18,020 likewise, depending upon its set of interactions that could lead 574 00:37:18,020 --> 00:37:20,820 to different forms of a protein being made in the first place. 575 00:37:20,820 --> 00:37:25,580 You know, opening up a site for phosphorylation or opening up 576 00:37:25,580 --> 00:37:26,740 a site for cleavage. 577 00:37:27,140 --> 00:37:28,580 Yes, absolutely. Yeah. 578 00:37:30,980 --> 00:37:35,860 That's incredibly complicated, but makes a lot of sense that biology 579 00:37:35,860 --> 00:37:39,790 doesn't isolate one action. It uses the tools at its disposal in 580 00:37:39,790 --> 00:37:44,070 a lot of different ways. And really what you're articulating is 581 00:37:44,070 --> 00:37:49,990 that there's this very tightly coupled relationship between proteoforms 582 00:37:49,990 --> 00:37:53,510 and IDP ensemble structures. 583 00:37:53,990 --> 00:37:58,830 Yes. Because, yeah, they're just finding. I feel like there are 584 00:37:58,830 --> 00:38:01,950 many, many, if I had to visualize it, it's like there are 585 00:38:01,950 --> 00:38:05,740 so many structures just going together and then there are. Is they. 586 00:38:05,740 --> 00:38:09,900 They find the energy minima and then they, they, they form that 587 00:38:09,900 --> 00:38:12,700 one protoform and that triggering thing could be maybe a 588 00:38:12,700 --> 00:38:16,380 ptm, could be a condition or could be a mutation as well. Could 589 00:38:16,380 --> 00:38:20,260 be, could be anything. That is just making them go into that proteoform. 590 00:38:20,260 --> 00:38:20,660 Like. 591 00:38:22,660 --> 00:38:25,060 That's, I'm going to be percolating on that for a while. 592 00:38:25,540 --> 00:38:31,180 And so you know, just from your perspective, what, so we, we 593 00:38:31,180 --> 00:38:34,340 talked a little bit about gaps in measurement. What are the other, 594 00:38:34,550 --> 00:38:38,590 are big barriers today to solving these problems of intrinsically 595 00:38:38,590 --> 00:38:41,590 disordered proteins? What are you most excited about in your lab 596 00:38:41,910 --> 00:38:45,110 that we're tackling this really big problem that's going to 597 00:38:45,190 --> 00:38:46,390 help us in this way? 598 00:38:48,630 --> 00:38:53,310 Yes. So in my lab I'm looking at what are the environments that 599 00:38:53,310 --> 00:38:57,150 could again let these proteins fold or misfold. And I think that 600 00:38:57,150 --> 00:39:00,700 is one problem. Like we don't even know how to recreate these in 601 00:39:01,420 --> 00:39:04,820 like what are the model systems to use? How do we even start? 602 00:39:04,820 --> 00:39:08,340 Like, where do we even start? Like a lot of proteins that I've 603 00:39:08,340 --> 00:39:12,740 been using are expressed in E. Coli, which do not have post translational 604 00:39:12,740 --> 00:39:16,259 modifications. And then I'm doing these very sophisticated biophysical 605 00:39:16,259 --> 00:39:20,540 measurements on that, which is very exciting too because I get to 606 00:39:20,540 --> 00:39:24,780 know some very basic rules. But then when I connect them to actual 607 00:39:24,940 --> 00:39:29,920 human patient biology, it's not translating. And what I see is 608 00:39:29,920 --> 00:39:34,400 like a lot of the translation gap. Like there are zero percent 609 00:39:35,200 --> 00:39:37,440 drugs that have been successful that came out of mice, 610 00:39:37,440 --> 00:39:41,360 for example. So it's like what my lab is trying to do, what I'm 611 00:39:41,360 --> 00:39:45,200 trying to do is bridge this fundamental knowledge like biophysics 612 00:39:45,360 --> 00:39:48,920 and then really bring it to what it means for patients, like 613 00:39:48,920 --> 00:39:52,440 the medical impacts. And what this could look like is looking at 614 00:39:52,440 --> 00:39:56,280 maybe doing some, some key biophysical experiments in the context 615 00:39:56,280 --> 00:40:03,200 of aging. So you know, looking at maybe patient like acquired, like 616 00:40:03,200 --> 00:40:06,480 material and then trying to come up with sophisticated methods 617 00:40:06,480 --> 00:40:09,640 or advanced methods to understand like can I, can I, can 618 00:40:09,640 --> 00:40:13,400 I bridge these two? So I think that is my goal, which is very fundamental, 619 00:40:13,400 --> 00:40:16,880 very basic questions and then applying that to patient outcomes. 620 00:40:17,040 --> 00:40:19,850 That's very interesting. I think one of the things that when 621 00:40:20,410 --> 00:40:24,250 sort of looking at some of your most recent papers, you were 622 00:40:24,250 --> 00:40:29,770 very much looking at protein variants. So in addition to context 623 00:40:29,770 --> 00:40:37,690 and environment, but questions of how isoforms potentially affect 624 00:40:37,690 --> 00:40:42,730 the set of shapes that can exist. And looking across not just 625 00:40:42,730 --> 00:40:46,600 in Alzheimer's disease, but this also seems to just be prevalent 626 00:40:46,600 --> 00:40:55,640 in cancer as, as well. And so in your mind when you, when we learn 627 00:40:55,640 --> 00:41:00,800 these things, it opens up, it opens up new diagnostics, it opens 628 00:41:00,800 --> 00:41:04,360 up potentially new types of therapeutics that are different than 629 00:41:04,360 --> 00:41:08,360 what we're applying today. What, what else does this really 630 00:41:08,360 --> 00:41:13,380 enable? Once we're able to study both the structural side and 631 00:41:13,620 --> 00:41:16,020 the proteoform side and put them together. 632 00:41:17,540 --> 00:41:22,420 So I mean, if you were to think of it from a disease diagnostic 633 00:41:22,420 --> 00:41:23,700 therapeutic point of view,. 634 00:41:23,940 --> 00:41:24,220 Then. 635 00:41:24,220 --> 00:41:27,259 We can really have better companion diagnostics as well because 636 00:41:27,259 --> 00:41:31,100 we, if we can understand how a protein is changing its shape and 637 00:41:31,100 --> 00:41:35,140 if we are able to detect it early on, then we can, we can really 638 00:41:35,220 --> 00:41:38,890 design a drug that binds to that shape shape and doesn't let 639 00:41:38,890 --> 00:41:44,450 it progress towards an aggregated state. So we can really 640 00:41:44,610 --> 00:41:50,690 have both diagnostics and therapeutics looking at these proteins 641 00:41:50,690 --> 00:41:53,250 rather than just drugging the protein and being like, yeah, we're 642 00:41:53,250 --> 00:41:56,810 going to find a drug, but here we can track it in people and then 643 00:41:56,810 --> 00:42:00,930 giving it to drugs. However, what I'm also fascinated about is 644 00:42:00,930 --> 00:42:04,330 it's not just disease. There are also functional amyloids and 645 00:42:04,330 --> 00:42:07,570 these are intrinsically disordered proteins and they can 646 00:42:07,810 --> 00:42:11,670 also form functional stuff. So are also these proteins, they can 647 00:42:11,670 --> 00:42:18,190 give rise to materials. And there are like, I mean when I was 648 00:42:18,190 --> 00:42:21,390 a PhD student I would see like a lot of slides showing spider silk 649 00:42:21,390 --> 00:42:24,870 which is like that's also protein. So you know, so, so these 650 00:42:24,870 --> 00:42:28,230 disordered proteins can be made to also like because they make 651 00:42:28,230 --> 00:42:31,150 functional materials. We can also use them in synthetic biology 652 00:42:31,150 --> 00:42:35,750 to like there's like a whole new toolkit that, that can be opened 653 00:42:35,750 --> 00:42:38,910 if you just understand the grammar or you know, the rules of 654 00:42:38,910 --> 00:42:41,730 these IDP is like how they fold, misfold and like what they're 655 00:42:41,730 --> 00:42:41,970 doing. 656 00:42:42,610 --> 00:42:46,010 That's, that's really crazy because I think, you know again when 657 00:42:46,010 --> 00:42:50,130 we think about biomaterials, we tend to think of wanting things 658 00:42:50,130 --> 00:42:55,490 that are incredibly structured and have a very specific shape that 659 00:42:55,570 --> 00:42:58,970 comes from what they do. But I think what you're saying is there's 660 00:42:58,970 --> 00:43:04,170 actually an entire other set of, of if you had idps you could 661 00:43:04,170 --> 00:43:07,410 create even newer, more interesting materials for further 662 00:43:07,570 --> 00:43:10,610 that are that go beyond what we've been able to create so far. 663 00:43:11,170 --> 00:43:14,130 Yeah, I mean it's. It. Yeah, definitely because they can do so 664 00:43:14,130 --> 00:43:16,770 many different things. It's just that only if we knew how to 665 00:43:16,770 --> 00:43:19,810 and to. If like, you know, to do that we need to understand those 666 00:43:19,810 --> 00:43:23,170 rules. How, how are they, how are they misfolding? Folding, not 667 00:43:23,170 --> 00:43:25,410 misfolding, but folding into all these different shapes. 668 00:43:26,610 --> 00:43:30,810 That's neat. Well, so tell. Maybe I'd like to transition a little 669 00:43:30,810 --> 00:43:36,920 bit to the, to just talking about the future and, and we just 670 00:43:36,920 --> 00:43:40,920 announced Congratulations. This large ARPA H funded consortium 671 00:43:40,920 --> 00:43:44,080 focused on intrinsically disordered proteins that you're co 672 00:43:44,080 --> 00:43:48,680 leading called seeds. Tell me a little bit about seeds. What it's 673 00:43:48,680 --> 00:43:51,440 hoping to do sort of its long term goals. 674 00:43:53,280 --> 00:43:57,440 Yeah. So also congratulations to you because Nautilus is our partner 675 00:43:58,320 --> 00:43:59,440 in this consortium. 676 00:43:59,600 --> 00:44:02,000 I am so excited to get to work on this with you. It's going to be 677 00:44:02,000 --> 00:44:02,430 a lot of fun. 678 00:44:02,980 --> 00:44:05,620 Yeah, it's going to be, it's like it's a dream project and this 679 00:44:05,620 --> 00:44:08,260 is exactly what I've been wanting to study for the last like 680 00:44:08,260 --> 00:44:13,380 many, many years. And it was just the perfect opportunity to bring 681 00:44:13,540 --> 00:44:16,660 all the fun people doing exciting things who can make this 682 00:44:16,660 --> 00:44:21,220 project possible for the question we've asked together. So 683 00:44:21,220 --> 00:44:24,260 in this SEEDS project we're answering that question. We're looking 684 00:44:24,260 --> 00:44:29,130 at how the environment and how the context is changing the shapes 685 00:44:29,130 --> 00:44:32,370 of these intrinsically disordered proteins. And we have 686 00:44:32,370 --> 00:44:36,010 partnered with Buck Institute for Research on Aging to form a super 687 00:44:36,010 --> 00:44:39,850 team. We have 10 academic partners and seven industry partners 688 00:44:39,850 --> 00:44:45,970 including Nautilus, whose the Voyager platform we'd be using to 689 00:44:45,970 --> 00:44:50,530 understand these isoforms, these proteoforms. And the goal for 690 00:44:50,530 --> 00:44:55,780 this project is to really understand IDPs across like in breadth 691 00:44:56,020 --> 00:44:59,660 and in depth. So I always liken this to you know, reading, 692 00:44:59,660 --> 00:45:02,620 understanding the grammar of like other style of an author which 693 00:45:02,620 --> 00:45:05,500 is like either read many books or just read one thing deeply enough 694 00:45:05,500 --> 00:45:08,460 to understand different ways of like what is the, what are the 695 00:45:08,460 --> 00:45:10,900 semantics. And that's exactly what we are doing. So we're going 696 00:45:10,900 --> 00:45:15,060 to look at many, many proteins and then we'll focus on two proteins 697 00:45:15,220 --> 00:45:21,540 which are tau and EWS fly one which is implicated in Ewing sarcoma, 698 00:45:21,540 --> 00:45:26,440 which is a pediatric cancer and tau is implic Alzheimer's disease, 699 00:45:26,440 --> 00:45:30,800 but also a range of taupathies. So we're really looking 700 00:45:30,880 --> 00:45:35,600 at how these proteins in different contexts, in different 701 00:45:35,680 --> 00:45:40,480 environments change their shapes. And then we will look at 702 00:45:40,480 --> 00:45:44,480 which of these shapes are related to a healthy outcome versus 703 00:45:44,480 --> 00:45:49,240 a diseased outcome. And we are bringing in different techniques 704 00:45:49,240 --> 00:45:54,690 altogether. So we are using high throughput and high resolution 705 00:45:54,690 --> 00:45:58,970 techniques. We have a cell free protein expression platform 706 00:45:59,770 --> 00:46:03,650 that can make thousands of variants at a time and we can expose 707 00:46:03,650 --> 00:46:06,690 it to thousands of conditions. You can think of what different permutations 708 00:46:06,690 --> 00:46:14,450 we can expose it to. And then we have a physics and chemistry based 709 00:46:14,450 --> 00:46:19,530 AI model that helps us use a lot of of this experimental biophysical 710 00:46:19,530 --> 00:46:25,170 data as restraints to capture what is possible. So AI can't do 711 00:46:25,170 --> 00:46:30,650 this on its own. The language models because there are force fields, 712 00:46:30,650 --> 00:46:34,090 there are rules. So we are really bringing in physics, chemistry, 713 00:46:34,570 --> 00:46:40,010 a breadth of biology, also patient biology. So we have clinicians 714 00:46:40,010 --> 00:46:43,370 on our team as well and we have patient cohorts who we'll be 715 00:46:43,610 --> 00:46:47,030 validating all our results into. So we not only like having 716 00:46:47,030 --> 00:46:51,630 like a hypothesis driven, data driven and we are predicting and 717 00:46:51,630 --> 00:46:54,590 then we are validating it into a disease. So this makes the whole 718 00:46:54,590 --> 00:46:59,270 consortium like, like a big giant. Like it's a dream project, 719 00:46:59,270 --> 00:47:02,910 that's what I call it because we are like we have everyone delivering 720 00:47:02,910 --> 00:47:06,470 onto solving one part of the puzzle. And this whole puzzle is 721 00:47:06,470 --> 00:47:10,750 like how does the environment change the shape of these proteins 722 00:47:10,750 --> 00:47:13,240 and leading to health or disease? Disease. 723 00:47:14,040 --> 00:47:17,240 And I think one of the challenges, the reason that all of 724 00:47:17,240 --> 00:47:20,560 the protein structure tools you mentioned, alphafold, they're 725 00:47:20,560 --> 00:47:23,800 dependent upon having a significant data corpus and people 726 00:47:23,800 --> 00:47:30,440 have been chipping away at the globular protein corpus since myoglobin 727 00:47:30,840 --> 00:47:36,680 and lysozyme. Way back the very first sperm whale myoglobin 728 00:47:37,080 --> 00:47:41,930 structures were solved. But for IDPs we just don't have the data 729 00:47:41,930 --> 00:47:46,690 resource to build the next generation models. And because they're 730 00:47:46,690 --> 00:47:51,290 so complex we really do need these physics informed models that, 731 00:47:51,690 --> 00:47:57,050 so we have a gap both in the training data and in the just AI 732 00:47:57,050 --> 00:48:01,450 methodologies to incorporate physics based models alongside the 733 00:48:01,450 --> 00:48:02,730 other canon. 734 00:48:03,130 --> 00:48:04,250 Exactly. Yes. 735 00:48:05,930 --> 00:48:11,710 That's very exciting. So going far? Future. Future. So 10 years 736 00:48:11,710 --> 00:48:20,030 from now, looking back, what, what do we now know about IDPs and 737 00:48:20,030 --> 00:48:26,350 how have they influenced the world? This is just a total prediction. 738 00:48:26,350 --> 00:48:29,510 There's no right answer. But from, from your viewpoint, you're 739 00:48:29,510 --> 00:48:32,430 looking back on the last 10 years of your career and on the field, 740 00:48:33,550 --> 00:48:34,270 where are we? 741 00:48:35,480 --> 00:48:41,680 I think we will have a foundational model that can predict 742 00:48:41,680 --> 00:48:45,000 these different ensembles of structures and tell what they are 743 00:48:46,600 --> 00:48:50,920 and from a health impact outcome. Knowing this knowledge will 744 00:48:50,920 --> 00:48:55,600 help us. We will be at a point where we have a diagnostic test that 745 00:48:55,600 --> 00:48:59,640 can predict which of these proteoforms are associated with different 746 00:48:59,640 --> 00:49:04,330 diseases. Diseases. So it's not just getting a multi omic, you 747 00:49:04,330 --> 00:49:08,130 know, a biomarker, like a panel, but it's really about these 748 00:49:08,130 --> 00:49:11,250 structures of these proteins and like people knowing which disease 749 00:49:11,250 --> 00:49:14,450 they have. Because currently it's super hard to diagnose Parkinson's, 750 00:49:14,530 --> 00:49:17,370 like people going with psp, cbd, they don't, they get a wrong 751 00:49:17,370 --> 00:49:22,970 diagnosis. So, so, so 10 years from now what I see is like people 752 00:49:22,970 --> 00:49:27,370 getting diagnosed early, which is helping families, but also drugs 753 00:49:27,370 --> 00:49:31,990 that are actually successful and available to people that, that, 754 00:49:31,990 --> 00:49:34,910 that can really, that can really address the, the cause of 755 00:49:34,910 --> 00:49:38,510 the disease. Yeah, that's, that's where I, that, that's where 756 00:49:38,510 --> 00:49:41,630 I would hope. But the other side of me also hopes to see like 757 00:49:41,630 --> 00:49:44,150 the functional aspects of these IDPs with, you know, people 758 00:49:44,150 --> 00:49:47,870 coming up with cool functions to, you know, like using them because 759 00:49:47,870 --> 00:49:50,070 they are proteins, they're the workhorses of the cell, they can 760 00:49:50,070 --> 00:49:53,350 do a lot of different things. So maybe using them in more creative 761 00:49:53,350 --> 00:49:56,390 and foundational ways of, of creating new things. 762 00:49:57,520 --> 00:50:02,360 That's a very exciting vision. Thank you again for joining us today. 763 00:50:02,360 --> 00:50:07,640 Just to sum up for our listeners, I think our key take homes 764 00:50:07,640 --> 00:50:14,640 are that drive basically all of biology, but that they've been 765 00:50:14,720 --> 00:50:17,720 pretty hard to study so far and that's why they're not talked 766 00:50:17,720 --> 00:50:22,280 about as much and why we don't understand them as well. Work that 767 00:50:22,280 --> 00:50:26,780 Priyanka and her colleagues are doing is really trying to open 768 00:50:26,780 --> 00:50:31,740 that black box so that we can understand how these critical proteins 769 00:50:31,820 --> 00:50:36,180 make biology go, make disease go, and then to modulate that in 770 00:50:36,180 --> 00:50:39,500 the future. And so it sounds like this is a very exciting moment 771 00:50:39,739 --> 00:50:42,380 for IDP biology where all these things are coming together 772 00:50:42,940 --> 00:50:45,900 to really transform the next decade. 773 00:50:47,100 --> 00:50:50,620 Yes, I'm super excited and I'm super excited to be working together 774 00:50:50,620 --> 00:50:51,740 as well on this project Problem. 775 00:50:51,900 --> 00:50:54,940 Oh, it's going to be so much fun. So thank, thank you everyone 776 00:50:54,940 --> 00:50:58,620 for joining us today on Translating Proteomics. Thank you 777 00:50:58,620 --> 00:51:02,300 to my guest Priyanka Joshi for joining us and sharing her perspective. 778 00:51:03,020 --> 00:51:05,820 Super fun having a chance to chat with you. Thank you. 779 00:51:06,460 --> 00:51:08,900 Thank you so much, Parag. It was super fun chatting with you as 780 00:51:08,900 --> 00:51:09,900 well. Thanks. 781 00:51:13,580 --> 00:51:17,300 We hope you enjoyed the Translating Proteomics podcast brought 782 00:51:17,300 --> 00:51:21,270 to you by Nautilus Biotechnology. To contact us or for 783 00:51:21,270 --> 00:51:25,670 further information, please email translatingproteomicsautilus 784 00:51:25,750 --> 00:51:26,230 Bio.